Warren W Pleskow: Influence Statistics

Warren W Pleskow

Warren W Pleskow

private practice, Encinitas, Calif | Radiant Research, Encinitas, California. | Radiant Research, Encinitas, California, USA. | Radiant Research, Encinitas, CaliforniaUSA | ...

Warren W Pleskow: Expert Impact

Concepts for which Warren W Pleskow has direct influence: Racemic albuterol , Fluticasone propionate , Seasonal allergic rhinitis , Moderate asthma , Levalbuterol racemic albuterol , Beclomethasone dipropionate , Asthmatic subjects .

Warren W Pleskow: KOL impact

Concepts related to the work of other authors for which for which Warren W Pleskow has influence: Fluticasone propionate , Aspirin desensitization , Allergic rhinitis , Racemic albuterol , Persistent asthma , Inhaled corticosteroids , Nasal polyps .

KOL Resume for Warren W Pleskow

Year
2008

private practice, Encinitas, Calif

2005

Radiant Research, Encinitas, California.

2004

Radiant Research, Encinitas, California, USA.

2003

Radiant Research, Encinitas, CaliforniaUSA

1999

Allergy and Asthma Centers of Charleston, Encinitas, California.

1998

Denver, Colo, Stockton and Encinitas, Calif, Wilmington, NC, and Marlborough, Mass

Scripps Memorial Hospital, Encinitas, California.

1996

Private Practice, Encinitas, California, U.S.A.

1995

Salt Lake City, Utah, Shreveport, La., Austin, Texas, Chester, Pa., Winston-Salem, N.C., Philadelphia, Pa., Fridley, Minn., San Jose, Calif., San Diego, Calif., Minneapolis, Minn., Houston, Texas, Bryan, Texas, Encinitas, Calif., San Antonio, Texas, and Kenilworth, N.J

1994

North Dartmouth, Mass., U.S.A.

1988

private practice, Encinitas, CA, USA

1984

Department of Allergy and Clinical Immunology, Kaiser Permanente Medical Center, San Diego, Calif., USA

1983

Department of Allergy and Clinical Immunology, Kaiser Petmanente Medical Center, San Diego, Calif., USA

1982

From the Department of Allergy and Clinical Immunology, Kaiser Permanente Medical Center-San Diego, San Diego, Calif. USA

Prominent publications by Warren W Pleskow

KOL-Index: 13659 . BACKGROUND: Fluticasone propionate is a topically active glucocorticoid with potent antiinflammatory activity in the treatment of asthma. OBJECTIVE: This study evaluated the safety and efficacy of fluticasone propionate administered via the Diskus and Diskhaler powder delivery devices in subjects with mild-to-moderate asthma. METHODS: Fluticasone propionate (500 microg twice daily) or ...
Known for Fluticasone Propionate | Treatment Asthma | Inhaled Corticosteroids | Efficacy Safety
KOL-Index: 12695 . BACKGROUND: The treatment of symptoms of seasonal allergic rhinitis often requires the use of a decongestant to improve nasal congestion, along with an antihistamine to adequately control other nasal, as well as nonnasal symptoms. METHODS: In this double-blind, placebo-controlled, multicenter study, 874 patients with moderate to severe symptoms of seasonal allergic rhinitis were treated ...
Known for Seasonal Allergic Rhinitis | Loratadine Pseudoephedrine | Treatment Symptoms | Nasal Congestion
KOL-Index: 12257 . BACKGROUND: Recent emphasis on the control of airway inflammation in asthma highlights the need for safe and effective antiinflammatory agents. Fluticasone propionate is one of the most potent antiinflammatory corticosteroids developed to date. OBJECTIVE: This study assessed the safety and efficacy of fluticasone propionate aerosol in the treatment of mild to moderate asthma. METHODS: ...
Known for Fluticasone Propionate | Moderate Asthma | 500 Micrograms | Airway Inflammation
KOL-Index: 11357 . BACKGROUND: Racemic albuterol is an equal mixture of (R)-albuterol (levalbuterol), which is responsible for the bronchodilator effect, and (S)-albuterol, which provides no benefit and may be detrimental. OBJECTIVE: We sought to compare 2 doses of a single enantiomer, levalbuterol (0.63 mg and 1.25 mg), and equivalent amounts of levalbuterol administered as racemic albuterol with placebo in ...
Known for Racemic Albuterol | Placebo Patients | 4 Weeks | Asthma Bronchodilator
KOL-Index: 11219 . The objectives of this study were to compare the efficacy and tolerability of twice-daily formoterol dry powder 12 microg and 24 microg (Foradil) delivered via Aerolizer inhaler with four times daily albuterol (salbutamol) 180 microg delivered via metered dose inhaler (MDI) and placebo. A total of 554 adolescents and adults (ages 12-75 years) with mild-to-moderate asthma were randomized to ...
Known for Formoterol Albuterol | 12 Microg | Dry Powder | Aerolizer Inhaler
KOL-Index: 9380 . BACKGROUND: Antihistamine-decongestant combination products generally provide more benefit than individual components for adequately treating patients who have seasonal allergic rhinitis (SAR) with moderate-to-severe nasal congestion. OBJECTIVE: To compare the effectiveness and safety of a 24-hour, extended-release formulation of desloratadine and pseudoephedrine with the individual ...
Known for Nasal Congestion | Allergic Rhinitis | Desloratadine Pseudoephedrine | Patients Sar
KOL-Index: 7178 . Thirty aspirin-sensitive asthmatic patients underwent incremental, oral aspirin challenge until a "positive reaction" (delta FEV1 greater than or equal to 25%) occurred. After this reaction, aspirin was readministered in an attempt to achieve "desensitization." This was defined as the ability of the patient to ingest 650 mg of aspirin without experiencing upper or lower respiratory-tract ...
Known for Aspirin Desensitization | Asthmatic Patients | Positive Reaction | Clinical Manifestations
KOL-Index: 4938 . Twenty-five ASA-sensitive patients with rhinosinusitis asthma underwent oral ASA challenges followed by desensitization to the adverse respiratory effects of ASA. We then compared the efficacy of continuous ASA treatment for their respiratory tract disease to that of a placebo treatment during a double-blind crossover study. For this group of 25 patients, there was significant improvement ...
Known for Rhinosinusitis Asthma | Desensitization Treatment | Nasal Symptoms | Oral Challenges
KOL-Index: 4606 . Nineteen aspirin sensitive adult patients were identified who experienced naso-ocular responses without associated bronchospasm during standardized oral aspirin challenge. These 19 patients exhibited the characteristics of the aspirin triad except asthma. These included hypertrophic rhinitis with or without associated nasal polyps, abnormal sinus roentgenograms, nasal eosinophilia, ...
Known for Aspirin Sensitive | Upper Airway | Nasal Polyps | Clinical Syndrome
KOL-Index: 4103 . In order to determine the types of respiratory responses observed during aspirin-induced reactions, 50 consecutive asthmatic patients with a history of aspirin sensitivity underwent prospective oral aspirin challenges between 1979 and 1981. Oral aspirin challenges produced 36 asthmatic responses (33 combined with rhinitis and three purely asthmatic) and six acute rhinoconjunctivitis ...
Known for Patients Aspirin | Respiratory Responses | Sensitive Rhinosinusitis | Drug Hypersensitivity
KOL-Index: 3919 . BACKGROUND: National and international guidelines recommend inhaled anti-inflammatory medications for patients with all but the mildest forms of asthma. Patients may also be more compliant with twice daily dosing. OBJECTIVE: To evaluate the efficacy and safety of triamcinolone acetonide (triamcinolone acetonide), 400 microg bid, in mild-to-moderate asthma patients. METHODS: A multicenter, ...
Known for Triamcinolone Acetonide | Adult Anti | Expiratory Volume | Administration Inhalation
KOL-Index: 2230 . BACKGROUND: The short-acting beta(2)-agonists levalbuterol and racemic albuterol are available for administration through a hydrofluoroalkane-134a (HFA) metered-dose inhaler (MDI). OBJECTIVE: This study compared the short-term safety and efficacy of cumulative doses of levalbuterol HFA MDI and racemic albuterol HFA MDI in asthmatic subjects. METHODS: This was a randomized, modified-blind, ...
Known for Racemic Albuterol | Beta Agonists | Bronchodilator Agents | Short Acting
KOL-Index: 2050
Known for Chronic Urticaria | Antagonists Humans | Histamine H1 | Cyproheptadine Double
KOL-Index: 1571 . Activation of complement was sought by two independent assay methods, total hemolytic complement (CH50) and C4 activation by rocket immunoelectrophoresis for C4d and C4 in plasma samples obtained from 16 aspirin-sensitive asthmatic patients and four control subjects during provocative oral aspirin challenges. No consistent evidence of significant complement activation was detected in ...
Known for Complement Activation | Aspirin Challenge | Asthmatic Patients

Key People For Racemic Albuterol

Top KOLs in the world
#1
Sidney S DeGraw
racemic albuterol pediatric patients placebo treatment
#2
George W Bensch
pulmicort turbuhaler mometasone furoate racemic albuterol
#3
David S Reasner
racemic albuterol pediatric patients placebo treatment
#4
Harold S Nelson
allergic rhinitis sublingual immunotherapy inhaled corticosteroids
#5
Warren W Pleskow
racemic albuterol fluticasone propionate seasonal allergic rhinitis
#6
Thomas E Rollins
racemic albuterol improved bronchodilation patients asthma

private practice, Encinitas, Calif | Radiant Research, Encinitas, California. | Radiant Research, Encinitas, California, USA. | Radiant Research, Encinitas, CaliforniaUSA | Allergy and Asthma Centers of Charleston, Encinitas, California.